Merck & Co.'s Solid Growth Turbo-Charged By Lagevrio For COVID-19
Even without Lagevrio, Merck's base business grew by double digits; the company raised its revenue guidance for the year.
You may also be interested in...
The CheckMate-901 trial failed on one of its primary endpoints, but the company will continue the trial to explore additional primary endpoints.
Group’s final report said evidence was inadequate to demonstrate a net health benefit versus symptomatic care for Lagevrio, a drug that has already taken a back seat to Pfizer’s Paxlovid.
The company credited generics’ late market entry, but that benefit is not expected to last; the firm lowered guidance for annual sales of the oncologic.